Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the ...

On Tuesday, Catalent Inc (CTLT) stock saw a decline, ending the day at $59.92 which represents a decrease of $-0.26 or -0.43% from the prior close of $60.18. The stock opened at $60.14 and touched a ...

Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...

The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...

Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is ...

Alessandro Maselli will remain president and CEO of Catalent (NYSE:CTLT) after its acquisition by Novo Holdings, according to an open letter to customers. In the letter addressing customers, Maselli ...

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, ...

Catalent (CTLT) issued the following open letter to customers: “I want to correct a few key inaccuracies that have been reported in the ...

Catalent, Inc. (CTLT) said, following the closing of transaction, as a private company under Novo Holdings' ownership, Catalent will ...

The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent ...

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised ...